CN Patent

CN112390796B — Kras g12c抑制剂及其在医药上的应用

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2023-06-27 · 3y expired

What this patent protects

本发明涉及一种新型化合物，其具有KRAS G12C调节活性。本发明还涉及这些化合物的制备方法以及包含其的药物组合物。

USPTO Abstract

本发明涉及一种新型化合物，其具有KRAS G12C调节活性。本发明还涉及这些化合物的制备方法以及包含其的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN112390796B
Jurisdiction
CN
Classification
—
Expires
2023-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Betta Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.